5U9 Stock Overview
A health supplements company, produces and distributes mushroom-derived products and related consumer packaged goods in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Psyched Wellness Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.058 |
| 52 Week High | CA$0.06 |
| 52 Week Low | CA$0.014 |
| Beta | 2.79 |
| 1 Month Change | 176.19% |
| 3 Month Change | 231.43% |
| 1 Year Change | 39.76% |
| 3 Year Change | -70.65% |
| 5 Year Change | n/a |
| Change since IPO | -14.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5U9 | DE Personal Products | DE Market | |
|---|---|---|---|
| 7D | 6.4% | -0.8% | -0.3% |
| 1Y | 39.8% | 4.7% | 4.5% |
Return vs Industry: 5U9 exceeded the German Personal Products industry which returned 4.7% over the past year.
Return vs Market: 5U9 exceeded the German Market which returned 4.5% over the past year.
Price Volatility
| 5U9 volatility | |
|---|---|
| 5U9 Average Weekly Movement | 55.3% |
| Personal Products Industry Average Movement | 4.7% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 5U9's share price has been volatile over the past 3 months.
Volatility Over Time: 5U9's weekly volatility has increased from 35% to 55% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Jeff Stevens | psyched-wellness.com |
Psyched Wellness Ltd., a health supplements company, produces and distributes mushroom-derived products and related consumer packaged goods in Canada. The company offers a line of Amanita Muscaria-derived water-based extracts, teas, and capsules to promote stress relief, relaxation, and assist with restful sleeping. It sells its products online.
Psyched Wellness Ltd. Fundamentals Summary
| 5U9 fundamental statistics | |
|---|---|
| Market cap | €19.25m |
| Earnings (TTM) | -€2.10m |
| Revenue (TTM) | €220.02k |
78.7x
P/S Ratio-8.3x
P/E RatioIs 5U9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5U9 income statement (TTM) | |
|---|---|
| Revenue | CA$326.00k |
| Cost of Revenue | CA$157.21k |
| Gross Profit | CA$168.80k |
| Other Expenses | CA$3.28m |
| Earnings | -CA$3.11m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.011 |
| Gross Margin | 51.78% |
| Net Profit Margin | -953.91% |
| Debt/Equity Ratio | 0% |
How did 5U9 perform over the long term?
See historical performance and comparison